enGene CFO Departs Amid 50% Workforce Reduction and Q2 Results
ENGN sits 23% above its 52-week low of $1.4 on light trading volume (0.3× avg).
Summary
enGene Therapeutics announced its Q2 2026 financial results, alongside a significant 50% workforce reduction and the departure of CFO Ryan Daws, effective July 15. This follows an earlier report today confirming the Q2 results and workforce cuts, which were implemented to extend the company's cash runway. The CFO's departure adds to the executive uncertainty during a period of major restructuring and financial pressure for the company. Investors will be watching for further details on the company's strategic direction and the planned BLA filing for detalimogene in the second half of 2026.
At the time of this announcement, ENGN was trading at $1.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $108.5M. The 52-week trading range was $1.40 to $12.25. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.